Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 11675 matches for

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Vial of the ChadOx (ChAdOx1 nCoV-2019) vaccine. Photo credit: John Cairns © John Cairns

Categories

Similar stories

TRIG celebrates huge success at International Congress of The Transplantation Society

The Translational Research Immunology Group (TRIG) at the Nuffield Department of Surgical Sciences has much to celebrate after winning five awards at the 30th International Congress of The Transplantation Society (TTS 2024) in Istanbul, Turkey, from 22 to 25 September.

Exploring science with us at IF Oxford

Four NDS academics awarded title of full professor